Higher natural levels of glucagon-like peptide-1 linked to brain inflammation and amyloid buildup in Alzheimer's disease

Alzheimer's disease is characterized by the presence of amyloid-β plaques, hyperphosphorylated tau tangles, and sustained neuroinflammation.

• Glucagon-like peptide-1 (GLP-1) is produced in the brain and has potential neuroprotective effects.
• GLP-1 receptor agonists (GLP-1RAs) have shown promising results in preclinical models of Alzheimer's disease.
• The effectiveness of GLP-1RAs in human clinical trials for Alzheimer's has been inconsistent.
• The role and behavior of endogenous GLP-1 in the progression of Alzheimer's disease are not well understood.
• Conflicting findings regarding GLP-1 in different patient groups highlight the need for further investigation.

Simplified